Kamada

Yahoo Finance • 5 days ago

Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva

Alvotech (NASDAQ: ALVO) tilkynnti í dag að mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hafi mælt með því að veita markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva, sem bæði innihalda virka e... Full story

Yahoo Finance • 7 days ago

Markaðsleyfi veitt í Japan fyrir þrjár nýjar líftæknilyfjahliðstæður frá Alvotech

REYKJAVÍK 19. september 2025 - Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að japanska heilbrigðis-, atvinnu- og velferðarráðuneytið hafi veitt Fuji Pharma Co. Ltd. („Fuji Pharma“), samstarfsaðila Alvotech í Japan, leyfi til markaðss... Full story

Yahoo Finance • 22 days ago

Alvotech tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley í New York

Alvotech (NASDAQ: ALVO) tekur þátt í 23. árlegu heilbrigðisráðstefnu fjárfestingabankans Morgan Stanley, sem haldin verður dagana 8.-10. september nk., í New York. Fundir með fjárfestum verða haldnir þriðjudaginn 9. september og Balaji Pra... Full story

Yahoo Finance • last month

KAMADA LTD (NASDAQ:KMDA) Reports Mixed Q2 2025 Earnings with Strong EPS Beat and Raised Profitability Guidance

KAMADA LTD (NASDAQ:KMDA [https://www.chartmill.com/stock/quote/KMDA/profile]) reported its second-quarter 2025 earnings, delivering mixed results relative to analyst expectations. While revenue slightly missed estimates, earnings per share... Full story

Yahoo Finance • last month

Vitiligo Treatment Strategic Market Research Report 2025-2030 | Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Vitiligo Treatment was estimated at US$1.5 Billion in 20... Full story

Yahoo Finance • 2 months ago

Alvotech kynnir uppgjör fyrri helmings ársins 2025 þann 14. ágúst nk. kl. 12 á hádegi

REYKJAVÍK (6. ágúst 2025) Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrri helming ársins 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 13. ágúst nk. Fundur til kynningar á uppgjörinu verður sendur út í b... Full story

Yahoo Finance • 2 months ago

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious con... Full story

Yahoo Finance • 3 months ago

Kamada confirms continuous business operations despite recent events in Middle East

* Kamada (NASDAQ:KMDA [https://seekingalpha.com/symbol/KMDA]) Tuesday said [https://seekingalpha.com/pr/20138521-kamada-confirms-continuous-global-business-operations-and-products-availability-despite]that while circumstances in the Midd... Full story

Yahoo Finance • 2 years ago

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-Year Third Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% Increase Ye... Full story

Yahoo Finance • 2 years ago

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions... Full story

Yahoo Finance • 2 years ago

Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

Kamada Ltd. The Extended Agreement Term is Until March 2026 The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB toKedrion in 2022 and Anticipates a Significant Increase in 2023 REHOVOT, Israel, and HOBOKEN, N... Full story

Yahoo Finance • 2 years ago

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

Kamada Ltd. REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious co... Full story

Yahoo Finance • 3 years ago

Kamada Announces Planned Transition of Chief Financial Officer

REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced t... Full story

Yahoo Finance • 3 years ago

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it... Full story

Yahoo Finance • 3 years ago

Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT

Trial Recruitment Beginning to Accelerate; 30 Patients Enrolled and Treated to DateIndependent Data Safety Monitoring Board (DSMB) Recommends Study Continuation Without Modification for Fourth Time Since Study InitiationBased on Encouragin... Full story

Yahoo Finance • 3 years ago

Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company, the Em... Full story

Yahoo Finance • 3 years ago

Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022

Kamada Ltd. REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will rele... Full story